129 related articles for article (PubMed ID: 20843454)
1. [Response and progression-free survival in T2 to T4 bladder tumors treated with trimodality therapy with bladder preservation].
Rincón Mayans A; Rosell Costa D; Zudaire Bergera JJ; Rioja Zuazu J; Barba Abad J; Tolosa Eizaguirre E; Romero Vargas L; Pascual Piedrola I
Actas Urol Esp; 2010 Oct; 34(9):775-80. PubMed ID: 20843454
[TBL] [Abstract][Full Text] [Related]
2. The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?
Wo JY; Shipley WU; Dahl DM; Coen JJ; Heney NM; Kaufman DS; Zietman AL
BJU Int; 2009 Jul; 104(2):179-83. PubMed ID: 19154448
[TBL] [Abstract][Full Text] [Related]
3. Downstaging and survival benefits of neoadjuvant radiotherapy before cystectomy for patients with invasive bladder carcinoma.
Granfors T; Tomic R; Ljungberg B
Scand J Urol Nephrol; 2009; 43(4):293-9. PubMed ID: 19363744
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
George L; Bladou F; Bardou VJ; Gravis G; Tallet A; Alzieu C; Serment G; Salem N
Urology; 2004 Sep; 64(3):488-93. PubMed ID: 15351577
[TBL] [Abstract][Full Text] [Related]
5. p53 and p21 Expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach.
Garcia del Muro X; Condom E; Vigués F; Castellsagué X; Figueras A; Muñoz J; Solá J; Soler T; Capellà G; Germà JR
Cancer; 2004 May; 100(9):1859-67. PubMed ID: 15112266
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy for muscle-invasive bladder cancer treated with definitive radiotherapy: persisting uncertainties.
Choueiri TK; Raghavan D
Nat Clin Pract Oncol; 2008 Aug; 5(8):444-54. PubMed ID: 18577983
[TBL] [Abstract][Full Text] [Related]
7. Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors.
Zietman AL; Sacco D; Skowronski U; Gomery P; Kaufman DS; Clark JA; Talcott JA; Shipley WU
J Urol; 2003 Nov; 170(5):1772-6. PubMed ID: 14532773
[TBL] [Abstract][Full Text] [Related]
8. Lymphovascular invasion of urothelial cancer in matched transurethral bladder tumor resection and radical cystectomy specimens.
Kunju LP; You L; Zhang Y; Daignault S; Montie JE; Lee CT
J Urol; 2008 Nov; 180(5):1928-32; discussion 1932. PubMed ID: 18801529
[TBL] [Abstract][Full Text] [Related]
9. Management of superficial recurrences in an irradiated bladder after combined-modality organ-preserving therapy.
Weiss C; Wittlinger M; Engehausen DG; Krause FS; Ott OJ; Dunst J; Sauer R; Rödel C
Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1502-6. PubMed ID: 17935905
[TBL] [Abstract][Full Text] [Related]
10. Current status of radiation therapy and combined-modality treatment for bladder cancer.
Rödel C
Strahlenther Onkol; 2004 Nov; 180(11):701-9. PubMed ID: 15549188
[TBL] [Abstract][Full Text] [Related]
11. Organ preservation for muscle-invasive bladder cancer by transurethral resection.
Leibovici D; Kassouf W; Pisters LL; Pettaway CA; Wu X; Dinney CP; Grossman HB
Urology; 2007 Sep; 70(3):473-6. PubMed ID: 17905099
[TBL] [Abstract][Full Text] [Related]
12. Organ-sparing treatment in muscle-invasive bladder cancer.
Dunst J; Diestelhorst A; Kühn R; Müller AC; Scholz HJ; Fornara P
Strahlenther Onkol; 2005 Oct; 181(10):632-7. PubMed ID: 16220401
[TBL] [Abstract][Full Text] [Related]
13. Favourable outcomes of patients with clinical stage T3N0M0 bladder cancer treated with induction low-dose chemo-radiotherapy plus partial or radical cystectomy vs immediate radical cystectomy: a single-institutional retrospective comparative study.
Koga F; Kihara K; Fujii Y; Yoshida S; Saito K; Masuda H; Kageyama Y; Kawakami S
BJU Int; 2009 Jul; 104(2):189-94. PubMed ID: 19154452
[TBL] [Abstract][Full Text] [Related]
14. An update of combined modality therapy for patients with muscle invading bladder cancer using selective bladder preservation or cystectomy.
Shipley WU; Kaufman DS; Heney NM; Althausen AF; Zietman AL
J Urol; 1999 Aug; 162(2):445-50; discussion 450-1. PubMed ID: 10411054
[TBL] [Abstract][Full Text] [Related]
15. Similar treatment outcomes for radical cystectomy and radical radiotherapy in invasive bladder cancer treated at a United Kingdom specialist treatment center.
Kotwal S; Choudhury A; Johnston C; Paul AB; Whelan P; Kiltie AE
Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):456-63. PubMed ID: 17904301
[TBL] [Abstract][Full Text] [Related]
16. Small cell carcinoma of the urinary bladder. The Mayo Clinic experience.
Choong NW; Quevedo JF; Kaur JS
Cancer; 2005 Mar; 103(6):1172-8. PubMed ID: 15700264
[TBL] [Abstract][Full Text] [Related]
17. Bladder conservation treatment in the elderly population: results and prognostic factors of muscle-invasive bladder cancer.
Tran E; Souhami L; Tanguay S; Rajan R
Am J Clin Oncol; 2009 Aug; 32(4):333-7. PubMed ID: 19381080
[TBL] [Abstract][Full Text] [Related]
18. [Combined therapy for patients with invasive bladder cancer].
Startsev VIu; Karelin MI
Vopr Onkol; 2003; 49(2):235-8. PubMed ID: 12785212
[TBL] [Abstract][Full Text] [Related]
19. Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy, and hyperfractionated radiotherapy: long term results.
Danesi DT; Arcangeli G; Cruciani E; Altavista P; Mecozzi A; Saracino B; Orefici F
Cancer; 2004 Dec; 101(11):2540-8. PubMed ID: 15481058
[TBL] [Abstract][Full Text] [Related]
20. Bladder-sparing multimodality treatment of muscle-invasive bladder cancer: a five-year follow-up.
Given RW; Parsons JT; McCarley D; Wajsman Z
Urology; 1995 Oct; 46(4):499-504; discussion 504-5. PubMed ID: 7571218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
